{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:05:44Z","timestamp":1787501144595,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Ovid Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40271-018-0323-7","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T21:02:54Z","timestamp":1531170174000},"page":"97-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A Conceptual Model of Angelman Syndrome and Review of Relevant Clinical Outcomes Assessments (COAs)"],"prefix":"10.1007","volume":"12","author":[{"given":"Joseph C.","family":"Grieco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emuella","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Cabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Visootsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"323_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajmg.a.31074","volume":"140A","author":"CA Williams","year":"2006","unstructured":"Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, Magenis RE, Moncla A, Schinzel AA, Summers JA, Wagstaff J. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet. 2006;140A:413\u20138. \n                    https:\/\/doi.org\/10.1002\/ajmg.a.31074\n                    \n                  .","journal-title":"Am J Med Genet"},{"issue":"3\u20135","key":"323_CR2","first-page":"100","volume":"2","author":"A Dagli","year":"2012","unstructured":"Dagli A, Buiting K, Williams CA. Molecular and Clinical Aspects of Angelman Syndrome. Mol Syndromol. 2012;2(3\u20135):100\u201312.","journal-title":"Mol Syndromol."},{"issue":"2","key":"323_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/jmg.40.2.87","volume":"40","author":"J Clayton-Smith","year":"2003","unstructured":"Clayton-Smith J, Laan LA. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet. 2003;40(2):87\u201395.","journal-title":"J Med Genet"},{"key":"323_CR4","unstructured":"Food and Drug Administration (FDA); US Department of Health and Human Services; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER); Center for Devices and Radiological Health (CDRH). Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf\n                    \n                   21-01-18. Accessed 21 Jan 2018."},{"issue":"6","key":"323_CR5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jval.2016.04.009","volume":"19","author":"MM Lowe","year":"2016","unstructured":"Lowe MM, Blaser DA, Cone L, Arcona S, Ko J, Sasane R, Wicks P. Increasing patient involvement in drug development. Value in Health. 2016;19(6):869\u201378.","journal-title":"Value in Health"},{"issue":"1","key":"323_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MLR.0000000000000273","volume":"53","author":"EM Perfetto","year":"2015","unstructured":"Perfetto EM, Burke L, Oehrlein EM, Epstein RS. Patient-focused drug development: a new direction for collaboration. Med Care. 2015;53(1):9\u201317.","journal-title":"Med Care"},{"issue":"8","key":"323_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/ajmg.a.33509","volume":"152","author":"SU Peters","year":"2010","unstructured":"Peters SU, Bird LM, Kimonis V, Glaze DG, Shinawi LM, Bichell TJ, Barbieri-Welge R, Nespeca M, Anselm I, Waisbren S, Sanborn E. Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid. Am J Med Genet Part A. 2010;152(8):1994\u20132001.","journal-title":"Am J Med Genet Part A"},{"issue":"12","key":"323_CR8","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1002\/ajmg.a.34297","volume":"155","author":"LM Bird","year":"2011","unstructured":"Bird LM, Tan WH, Bacino CA, Peters SU, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, Gentile JK, Glaze DG, Horowitz LT. A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. Am J Med Genet Part A. 2011;155(12):2956\u201363.","journal-title":"Am J Med Genet Part A"},{"key":"323_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbr.2012.12.052","volume":"243","author":"HS Huang","year":"2013","unstructured":"Huang HS, Burns AJ, Nonneman RJ, Baker LK, Riddick NV, Nikolova VD, Riday TT, Yashiro K, Philpot BD, Moy SS. Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res. 2013;243:79\u201390.","journal-title":"Behav Brain Res"},{"key":"323_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156439","author":"AM Mabb","year":"2016","unstructured":"Mabb AM, Simon JM, King IF, Lee HM, An LK, Philpot BD, Zylka MJ. Topoisomerase 1 regulates gene expression in neurons through cleavage complex-dependent and-independent mechanisms. PLoS One. 2016. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0156439\n                    \n                  .","journal-title":"PLoS One"},{"issue":"7465","key":"323_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nature12553","volume":"501","author":"RN Plasschaert","year":"2013","unstructured":"Plasschaert RN, Bartolomei MS. Autism: a long genetic explanation. Nature. 2013;501(7465):36.","journal-title":"Nature"},{"issue":"7539","key":"323_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature13975","volume":"518","author":"L Meng","year":"2015","unstructured":"Meng L, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature. 2015;518(7539):409.","journal-title":"Nature"},{"key":"323_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/mt.2015.236","volume":"3","author":"BJ Bailus","year":"2016","unstructured":"Bailus BJ, Pyles B, McAlister MM, O\u2019geen H, Lockwood SH, Adams AN, Nguyen JT, Yu A, Berman RF, Segal DJ. Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an Angelman syndrome mouse brain. Mol Ther. 2016;3:548\u201355.","journal-title":"Mol Ther"},{"key":"323_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12883-014-0232-x","volume":"1","author":"JC Grieco","year":"2014","unstructured":"Grieco JC, Ciarlone SL, Gieron-Korthals M, Schoenberg MR, Smith AG, Philpot RM, Heussler HS, Banko JL, Weeber EJ. An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome. BMC Neurol. 2014;1:232.","journal-title":"BMC Neurol"},{"issue":"2","key":"323_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/qshc.1.2.87","volume":"1","author":"A Frater","year":"1992","unstructured":"Frater A. Health outcomes: a challenge to the status quo. Qual Health Care. 1992;1(2):87\u20138.","journal-title":"Qual Health Care"},{"issue":"4","key":"323_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1547-5069.2005.00058.x","volume":"37","author":"CE Ferrans","year":"2005","unstructured":"Ferrans CE, Zerwic JJ, Wilbur JE, Larson JL. Conceptual model of health-related quality of life. J Nurs Scholarsh. 2005;37(4):336\u201342.","journal-title":"J Nurs Scholarsh"},{"key":"323_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13023-017-0716-z","volume":"12","author":"AC Wheeler","year":"2017","unstructured":"Wheeler AC, Sacco P, Cabo R. Unmet clinical needs and burden in Angelman syndrome: a review of the literature. Orphanet J Rare Dis. 2017;12:164\u201381.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"323_CR18","doi-asserted-by":"publisher","first-page":"A386","DOI":"10.1016\/j.jval.2016.09.225","volume":"19","author":"L Abetz-Webb","year":"2016","unstructured":"Abetz-Webb L, Cabo R, Grieco J, Rakhit A, During M. Conceptual model and clinical outcomes assessments for Angelman\u2019s syndrome: utilizing pragmatic methods in rare diseases. Value Health. 2016;19(7):A386.","journal-title":"Value Health"},{"key":"323_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ridd.2012.10.001","volume":"34","author":"KD Allen","year":"2013","unstructured":"Allen KD, Kuhn BR, DeHaai KA, Wallace DP. Evaluation of a behavioral treatment package to reduce sleep problems in children with Angelman syndrome. Res Dev Disabil. 2013;34:676\u201386.","journal-title":"Res Dev Disabil"},{"key":"323_CR20","first-page":"136","volume":"4","author":"D Phillips","year":"2015","unstructured":"Phillips D, Griffin D, Przybylski T, Morrison E, Reeves A, Vallee M, Fujita K, Madson K, Whyte M. A modified performance-oriented mobility assessment tool for assessing clinically relevant gait impairments and change in children with hypophosphatasia: development and validation. Bone Abstract. 2015;4:136.","journal-title":"Bone Abstract"},{"issue":"3","key":"323_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/00222895.2015.1084986","volume":"48","author":"A Gouelle","year":"2015","unstructured":"Gouelle A, Leroux J, Bredin J, Megrot F. Changes in gait variability from first steps to adulthood: nromative data for the gait variability Index. J Motor Behavior. 2015;48(3):249\u201355.","journal-title":"J Motor Behavior"},{"key":"323_CR22","volume-title":"PEDI-CAT: development, standardization and administration manual","author":"SM Haley","year":"2012","unstructured":"Haley SM, Coster WJ, Dumas HM, Fragala-Pinkham MA, Moed R. PEDI-CAT: development, standardization and administration manual. Boston: Boston University; 2012."},{"issue":"6","key":"323_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1023\/B:JADD.0000005999.27178.55","volume":"33","author":"AJ Esbensen","year":"2003","unstructured":"Esbensen AJ, Rojahn J, Aman MG, Ruedrich S. Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. J Autism Dev Disord. 2003;33(6):617\u201329.","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"323_CR24","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485\u201391.","journal-title":"Am J Ment Defic"},{"key":"323_CR25","first-page":"56","volume-title":"Research methods for clinical and health psychology","author":"H Joffe","year":"2004","unstructured":"Joffe H, Yardley L. Content and thematic analysis. In: Marks D, Yardley L, editors. Research methods for clinical and health psychology. London: Sage; 2004. p. 56\u201368."},{"key":"323_CR26","unstructured":"MaxQDA, software for qualitative data analysis, 1989\u20132018, VEBI Software\u2014Consult\u2014Sozialforschung GmbH, Berlin, Germany."},{"issue":"3","key":"323_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/erp.10.30","volume":"10","author":"C Kerr","year":"2010","unstructured":"Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):269\u201381.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"323_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2788.2011.01386.x","volume":"55","author":"GM Griffith","year":"2011","unstructured":"Griffith GM, Hastings RP, Oliver C, Howlin P, Moss J, Petty J, Tunnicliffe P. Psychological well-being in parents of children with Angelman, Cornelia de Lange and Cri du Chat syndromes. J Intellect Disabil Res. 2011;55(4):397\u2013410.","journal-title":"J Intellect Disabil Res"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-018-0323-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T12:17:06Z","timestamp":1568722626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-018-0323-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1007\/s40271-018-0323-7","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"10 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Ovid Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding statement"}},{"value":"J.C. Grieco, R. Cabo, and J. Visootsak are employees of Ovid Therapeutics and\u00a0own stock in Ovid Therapeutics. B. Romero and E. Flood are employees of ICON, which was hired by Ovid to conduct this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study received approval from Salus IRB (Austin, TX, USA), a central institutional review board. All study participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Consent"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}